Atrial fibrillation in breast cancer therapy: does tamoxifen confer a lower risk than aromatase inhibitors?
AI use is associated with a higher risk of AF than tamoxifen in the first 5 years of treatment, but the risk equalizes at 10 years. Long-term hormonal therapy has an increased risk of AF, highlighting the need for ongoing monitoring and management of risk factors.
Authors
- Samuel Mensah (ORCID: https://orcid.org/0000-0002-0835-5450)
- Jennifer M. Kwan (ORCID: https://orcid.org/0000-0002-4715-1848)
- Hamza A Rashid (ORCID: https://orcid.org/0000-0002-3505-4768)
- Grace Appah
- Patrick Kwaah (ORCID: https://orcid.org/0000-0002-8524-4615)
- Emmanuel Ababio Agyemang (ORCID: https://orcid.org/0009-0001-1998-2281)
- Abraham Carboo (ORCID: https://orcid.org/0009-0002-3892-878X)
- Joseph S. Kekrebesi (ORCID: https://orcid.org/0009-0002-1078-0250)
- Daniil Katkov
Institutions
- West Virginia University (US)
- Newark Beth Israel Medical Center (US)
- Emory University (US)
- Yale University (US)
- Waterbury Hospital (US)
Publication Details
- Journal
- Cardio-Oncology
- Published
- 2025-05-31
- DOI
- https://doi.org/10.1186/s40959-025-00352-3
- Citations
- 1
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 1.82